REGENXBIO Inc.
DE ˙ DB ˙ US75901B1070
€ 6,20 ↓ -0.10 (-1.59%)
2026-06-02
PREÇO DA AÇÃO
SecurityDE:RB0 / REGENXBIO Inc.
InstitutionFmr Llc
Latest Disclosed Ownership940,942 shares
Ownership 2.62%
Fmr Llc ownership in RB0 / REGENXBIO Inc.

2019-02-13 - Fmr Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 940,942 shares of REGENXBIO Inc. (DE:RB0). This represents 2.625 percent ownership of the company. In their previous filing dated 2018-02-13 , Fmr Llc had reported owning 2,091,594 shares, indicating a decrease of -55.01 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2019-02-13 2019-02-13 13G/A 2,091,594 940,942 -55.01 2.62 -60.91
2018-02-13 2018-02-13 13G/A 2,285,794 2,091,594 -8.50 6.71 -22.22
2017-02-14 2017-02-14 13G/A 1,961,347 2,285,794 16.54 8.63 15.94
2016-06-30 2016-06-30 13G/A 3,312,462 1,961,347 -40.79 7.45 -40.85
2016-02-12 2016-02-12 13G/A 2,952,686 3,312,462 12.18 12.59 8.08
2015-09-25 2015-09-25 13G 2,952,686 11.65

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F REGENXBIO COM 75901B107 311,268 45,173 16.98 2,608 -31.92 0.0000
2026-02-17 2025-12-31 13F REGENXBIO COM 75901B107 266,095 70,905 36.33 3,832 103.45 0.0002
2025-11-13 2025-09-30 13F REGENXBIO COM 75901B107 195,190 23,671 13.80 1,884 33.74 0.0001
2025-08-14 2025-06-30 13F REGENXBIO COM 75901B107 171,519 3,135 1.86 1,408 17.04 0.0001
2025-05-12 2025-03-31 13F REGENXBIO COM 75901B107 168,384 166,828 10,721.59 1,204 9,925.00 0.0001
2025-02-13 2024-12-31 13F REGENXBIO COM 75901B107 1,556 -1,093 -41.26 12 -55.56 0.0000
2024-11-13 2024-09-30 13F REGENXBIO COM 75901B107 2,649 1,656 166.77 28 145.45 0.0000
2024-08-13 2024-06-30 13F REGENXBIO COM 75901B107 993 -517 -34.24 12 -64.52 0.0000
2024-05-13 2024-03-31 13F REGENXBIO COM 75901B107 1,510 -588 -28.03 32 -16.22 0.0000
2024-02-13 2023-12-31 13F REGENXBIO COM 75901B107 2,098 -207 -8.98 38 0.00 0.0000
2023-11-13 2023-09-30 13F REGENXBIO COM 75901B107 2,305 295 14.68 38 -7.50 0.0000
2023-08-11 2023-06-30 13F REGENXBIO COM 75901B107 2,010 -120 -5.63 40 0.00 0.0000
2023-08-11 2023-03-31 13F/A-1 REGENXBIO COM 75901B107 2,130 -29,658 -93.30 40 -94.44 0.0000
2023-05-11 2023-03-31 13F REGENXBIO COM 75901B107 2,130 -29,658 40 0.0000
2023-02-13 2022-12-31 13F REGENXBIO COM 75901B107 31,788 125 0.39 721 -13.98 0.0001
2022-11-10 2022-09-30 13F REGENXBIO COM 75901B107 31,663 71 0.22 837 7.31 0.0001
2022-08-12 2022-06-30 13F REGENXBIO COM 75901B107 31,592 20,663 189.07 780 114.88 0.0001
2022-05-13 2022-03-31 13F REGENXBIO COM 75901B107 10,929 7,277 199.26 363 205.04 0.0000
2022-02-14 2021-12-31 13F REGENXBIO COM 75901B107 3,652 -52,980 -93.55 119 -94.99 0.0000
2022-02-14 2021-09-30 13F/A-1 REGENXBIO COM 75901B107 56,632 41,492 274.06 2,374 303.74 0.0002
2021-11-15 2021-09-30 13F REGENXBIO COM 75901B107 56,632 41,492 2,374 0.0000
2021-08-13 2021-06-30 13F REGENXBIO COM 75901B107 15,140 9 0.06 588 13.95 0.0000
2021-05-14 2021-03-31 13F REGENXBIO COM 75901B107 15,131 23 0.15 516 -24.67 0.0000
2021-02-08 2020-12-31 13F REGENXBIO COM 75901B107 15,108 -3,800 -20.10 685 31.73 0.0001
2020-11-13 2020-09-30 13F REGENXBIO COM 75901B107 18,908 -100,900 -84.22 520 -88.22 0.0001
2020-08-24 2020-06-30 13F/A-1 REGENXBIO COM 75901B107 119,808 -274,900 -69.65 4,413 -65.47 0.0005
2020-08-13 2020-06-30 13F REGENXBIO COM 75901B107 119,808 -274,900 4,413 108.4145
2020-05-14 2020-03-31 13F REGENXBIO COM 75901B107 394,708 -33,400 -7.80 12,781 -27.13 0.0018
2020-02-07 2019-12-31 13F REGENXBIO COM 75901B107 428,108 -16,900 -3.80 17,540 10.72 0.0019
2019-11-13 2019-09-30 13F REGENXBIO COM 75901B107 445,008 -101,886 -18.63 15,842 -43.61 0.0019
2019-08-13 2019-06-30 13F REGENXBIO COM 75901B107 546,894 -316,400 -36.65 28,094 -43.22 0.0033
2019-05-13 2019-03-31 13F REGENXBIO COM 75901B107 863,294 -77,648 -8.25 49,475 25.34 0.0059
2019-02-13 2018-12-31 13F REGENXBIO COM 75901B107 940,942 -153,852 -14.05 39,472 -52.25 0.0054
2018-11-09 2018-09-30 13F REGENXBIO COM 75901B107 1,094,794 -529,000 -32.58 82,657 -29.05 0.0093
2018-08-10 2018-06-30 13F REGENXBIO COM 75901B107 1,623,794 -389,700 -19.35 116,507 93.85 0.0138
2018-05-14 2018-03-31 13F REGENXBIO COM 75901B107 2,013,494 -78,100 -3.73 60,103 -13.58 0.0071
2018-02-12 2017-12-31 13F REGENXBIO COM 75901B107 2,091,594 -136,100 -6.11 69,546 -5.25 0.0082
2017-11-13 2017-09-30 13F REGENXBIO COM 75901B107 2,227,694 -44,800 -1.97 73,403 63.55 0.0089
2017-08-29 2017-06-30 13F/A-1 REGENXBIO COM 75901B107 2,272,494 -2,100 -0.09 44,882 2.24 0.0056
2017-08-11 2017-06-30 13F REGENXBIO COM 75901B107 2,272,494 -2,100 44,882
2017-05-11 2017-03-31 13F REGENXBIO COM 75901B107 2,274,594 -11,200 -0.49 43,900 3.54 0.0056
2017-02-10 2016-12-31 13F REGENXBIO COM 75901B107 2,285,794 1,425,664 165.75 42,401 251.88 0.0057
2016-11-14 2016-09-30 13F REGENXBIO COM 75901B107 860,130 -1,062,452 -55.26 12,050 -21.66 0.0016
2016-08-11 2016-06-30 13F REGENXBIO COM 75901B107 1,922,582 -1,154,479 -37.52 15,381 -53.72 0.0021
2016-05-16 2016-03-31 13F REGENXBIO COM 75901B107 3,077,061 -229,801 -6.95 33,232 -39.46 0.0046
2016-02-12 2015-12-31 13F REGENXBIO COM 75901B107 3,306,862 232,296 7.56 54,894 -18.96 0.0074
2015-11-10 2015-09-30 13F REGENXBIO COM 75901B107 3,074,566 3,074,566 67,733 0.0096
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.